medwireNews: Recommendations for the local and systemic treatment of patients with breast cancer and germline mutations in breast cancer susceptibility genes have been issued by the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO).
The recommendations aim to assist healthcare professionals in managing their patients with early or advanced disease and germline mutations in BRCA1, BRCA2, PALB2, CHEK2, ATM, and TP53, providing guidance on the optimal surgery, radiotherapy, and systemic therapy options for these patients.
For instance, the guideline authors recommend that breast-conserving surgery be considered for BRCA mutation carriers with newly diagnosed disease and advise against withholding radiotherapy for ATM carriers. More details are available in the article published in the Journal of Clinical Oncology.
The evidentiary basis for the guidelines is a systematic review of 58 articles for the local therapy and six randomized controlled trials for the systemic therapy recommendations, and the guidance is based primarily on a formal consensus process.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group
J Clin Oncol 2020; doi:10.1200/JCO.20.00299